Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
- EUR | -.--% | -0,40% | -.--% |
16:26 | GSK zegt dat depemokimab astma-aanvallen vermindert in 2 late-fase studies | MT |
09:50 | GSK's depemokimab astmabehandeling voldoet aan eindpunten in laatste onderzoeken | AN |
Omzet 2024 * | 31,63 mld. 40,22 mld. 37,06 mld. | Omzet 2025 * | 33,58 mld. 42,71 mld. 39,35 mld. | Marktkapitalisatie | 72,39 mld. 92,05 mld. 84,81 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 5,54 mld. 7,05 mld. 6,5 mld. | Nettowinst (verlies) 2025 * | 6,49 mld. 8,26 mld. 7,61 mld. | EV/omzet 2024 * | 2,68 x |
Nettoschuld 2024 * | 12,29 mld. 15,62 mld. 14,4 mld. | Nettoschuld 2025 * | 9,07 mld. 11,53 mld. 10,62 mld. | EV/omzet 2025 * | 2,43 x |
K/w-verhouding 2024 * |
12,9
x | K/w-verhouding 2025 * |
11,1
x | Werknemers | - |
Dividendrendement 2024 * |
3,43% | Dividendrendement 2025 * |
3,56% | Vrij verhandelbaar | 94,54% |
Recentste transcriptie over GlaxoSmithKline plc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 01-05-10 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 01-05-23 |
James Ford
CMP | Compliance Officer | - | 01-08-95 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 01-05-23 |
Jonathan Symonds
CHM | Chairman | 66 | 01-09-19 |
Hal Barron
BRD | Director/Board Member | 62 | 01-01-18 |
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+37,15% | 705 mld. | |
+32,42% | 583 mld. | |
-3,11% | 364 mld. | |
+20,18% | 332 mld. | |
+5,69% | 291 mld. | |
+16,81% | 238 mld. | |
-3,60% | 210 mld. | |
+10,46% | 209 mld. | |
+9,39% | 169 mld. |